SCHEMBL2535852

SCHEMBL2535852

CC(=Cc1ccc(O)c(O)c1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 7/20 0.57
AKR1C3 P42330 2/20 0.57
IAPP P10997 3/20 0.55
PTGS1 P23219 1/20 0.55
ABL1 P00519 1/20 0.54
ABL2 P42684 1/20 0.54
KDM4E B2RXH2 6/20 0.52
HSD17B10 Q99714 5/20 0.52
MEN1 O00255 4/20 0.52
ALDH1A1 P00352 4/20 0.52
MAPT P10636 4/20 0.52
HPGD P15428 4/20 0.52
KMT2A Q03164 4/20 0.52
TDP1 Q9NUW8 3/20 0.52
LMNA P02545 3/20 0.52
CYP3A4 P08684 3/20 0.52
MAPK1 P28482 3/20 0.52
PMP22 Q01453 3/20 0.52
HIF1A Q16665 3/20 0.52
NFKB1 P19838 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10554055 1.00 EGFR (0.57) EGFRAKR1C3IAPPPTGS1ABL1
SCHEMBL3423297 0.89 AKR1C3 (0.53) EGFRAKR1C3IAPPPTGS1ABL1
SCHEMBL8746634 0.89 AKR1C3 (0.53) EGFRAKR1C3IAPPPTGS1ABL1
SCHEMBL9613588 0.86 IAPP (0.56) EGFRAKR1C3IAPPPTGS1ABL1
SCHEMBL171076 0.85 AKR1C3 (0.53) EGFRAKR1C3IAPPPTGS1ABL1
Methylcaffeate SCHEMBL887921 0.84 APP (0.76) IAPPPTGS1KDM4EHSD17B10MEN1
Methylcaffeate SCHEMBL30604508 0.84 APP (0.76) IAPPPTGS1KDM4EHSD17B10MEN1
SCHEMBL14086414 0.84 AKR1C3 (0.52) EGFRAKR1C3IAPPPTGS1ABL1
SCHEMBL2085780 0.84 AKR1C3 (0.52) EGFRAKR1C3IAPPPTGS1ABL1
SCHEMBL2085781 0.84 AKR1C3 (0.52) EGFRAKR1C3IAPPPTGS1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112485345-B Comprehensive analysis method for chemical components of compound antidotal agent of antelope horn 山东宏济堂制药集团股份有限公司 2023-02-17 CN claimed
CN-110746302-B Method for separating and preparing phenolic acid compounds in echinacea purpurea 山东省分析测试中心 2022-04-22 CN claimed
CN-110746302-A Method for separating and preparing phenolic acid compounds in echinacea purpurea 山东省分析测试中心 2020-02-04 CN claimed
US-20260096984-A1 Implantable Device for Administering a Therapeutic Agent CELANESE EVA PERFORMANCE POLYMERS LLC (US) 2026-04-09 US disclosed
US-20260096985-A1 Injectable Composition For Drug Delivery CELANESE EVA PERFORMANCE POLYMERS LLC 2026-04-09 US disclosed
US-20260097150-A1 Implantable Device for Treating an Ocular Condition CELANESE EVA PERFORMANCE POLYMERS LLC (US) 2026-04-09 US disclosed
CN-117250300-B Method for detecting multiple components in Tibetan medicine twenty-five-flavor big soup pill 江西中医药大学 2024-02-20 CN disclosed
CN-117250300-A Method for detecting multiple components in Tibetan medicine twenty-five-flavor big soup pill 江西中医药大学 2023-12-19 CN disclosed
WO-2023230574-A1 ENGINEERED PHENYLALANINE AMMONIA LYASE AND TYROSINE AMMONIA LYASE ENZYMES FOR PRODUCING AROMATIC COMPOUNDS GINKGO BIOWORKS, INC. (US) 2023-11-30 WO disclosed
CN-110746302-B Method for separating and preparing phenolic acid compounds in echinacea purpurea 山东省分析测试中心 2022-04-22 CN disclosed
EP-3328498-B1 MEDICAL KIT COMPRISING HERBAL COMBINATIONS FOR TREATING PSORIASIS SIRBAL LTD (CY) 2021-05-05 EP disclosed
WO-2002014497-A2 GENES ENCODING MUTANT P-COUMARATE 3-HYDROXYLASE (C3H) AND METHODS OF USE PURDUE RESEARCH FOUNDATION (US) 2002-02-21 WO disclosed
EP-1007743-A2 ENZYMES MIXTURE Rhone-Poulenc Animal Nutrition S.A. (FR) 2000-06-14 EP disclosed
WO-1999057325-A2 ENZYMES MIXTURE RHONE-POULENC ANIMAL NUTRITION S.A. (FR) 1999-11-11 WO disclosed
US-5426210-A Water soluble sunscreen agents SHISEIDO CO., LTD. (JP) 1995-06-20 US disclosed
EP-0539601-A1 CINNAMIC ACID/GLYCEROL ADDUCT, ULTRAVIOLET ABSORBER, AND DERMATOLOGIC PREPARATION SHISEIDO COMPANY LIMITED (JP) 1993-05-05 EP disclosed
US-4870019-A SACCHAROTHRIX AMERICAN CYANAMID COMPANY (US) 1989-09-26 US disclosed
US-4699790-A FERMENTATION OF SACCHAROTHRIX EXPANAENSIS AMERICAN CYANAMID COMPANY (US) 1987-10-13 US disclosed
EP-0051667-B1 POLYMERS OF POLYKETENE ACETALS AND POLYOLS SRI INTERNATIONAL (US) 1986-03-05 EP disclosed
US-4304767-A POLYORTHOESTERS, BIODEGRADATION SRI INTERNATIONAL (US) 1981-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097150-A1 Implantable Device for Treating an Ocular Condition P4HTM, ITGAM, TIMM44 EGFR 1011/4885AKR1C3 914/4885IAPP 762/4885
US-20260096984-A1 Implantable Device for Administering a Therapeutic Agent GHITM, O60361, P4HTM EGFR 388/4885AKR1C3 4108/4885IAPP 785/4885
US-20260096985-A1 Injectable Composition For Drug Delivery SAMM50, OPRM1, IRAK4 EGFR 316/4885AKR1C3 1920/4885IAPP 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.